Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xenetic Biosciences Inc

2.79
+0.09743.61%
Post-market: 2.860.0676+2.42%16:00 EDT
Volume:7.45K
Turnover:20.93K
Market Cap:4.31M
PE:-1.09
High:2.86
Open:2.83
Low:2.68
Close:2.70
Loading ...

Company Profile

Company Name:
Xenetic Biosciences Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
2
Office Location:
945 Concord Street,Framingham,Massachusetts,United States
Zip Code:
01701
Fax:
- -
Introduction:
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Directors

Name
Position
Adam Logal
Chairman of the Board
Jeffrey F. Eisenberg
Chief Executive Officer and Director
Alexey Vinogradov
Director
Dmitry Genkin
Director
Firdaus Jal Dastoor
Director
Grigory Borisenko
Director
James Callaway
Director
Moshe Mizrahy
Director
Roger Kornberg
Director

Shareholders

Name
Position
Jeffrey F. Eisenberg
Chief Executive Officer and Director
James Parslow
Chief Financial Officer and Corporate Secretary
Curtis Lockshin
Chief Scientific Officer